Bringing DNA vaccines closer to commercial use.
Progress in the application of DNA vaccines as an immunization protocol is evident from the increasing number of such vaccines under evaluation in clinical trials and by the recent approval of several DNA vaccine products for veterinary applications. DNA vaccine technology offers important therapeutic and commercial advantages compared with conventional approaches, including the opportunity to target pathogens characterized by significant genetic diversity using a safe immunization platform, and the ability to use a simple, rapid and well-characterized production method. However, further optimization of DNA vaccine technology through the use of improved constructs, delivery systems and immunization protocols is necessary to clinically achieve the promising results that have been demonstrated in preclinical models.
Instituto Superior Técnico, Avenue Rovisco Pais 1, 1049-001 Lisbon, Portugal.
Joana A
JA
Carvalho
Duarte M F
DM
Prazeres
Gabriel A
GA
Monteiro
D000818:Animals; D002986:Clinical Trials as Topic / Q000191:economics / Q000639:trends; D003132:Commerce / Q000191:economics*; D055808:Drug Discovery / Q000191:economics / Q000639:trends; D006801:Humans; D013678:Technology, Pharmaceutical / Q000191:economics* / Q000639:trends; D019444:Vaccines, DNA / Q000191:economics* / Q000627:therapeutic use
D019444:Vaccines, DNA